These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29696406)

  • 41. Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment.
    Kwon HJ; Park Y; Nam SK; Kang E; Kim KK; Jeong I; Kwak Y; Yoon J; Kim TY; Lee KW; Oh DY; Im SA; Kong SH; Park DJ; Lee HJ; Kim HH; Yang HK; Lee HS
    Cancer Med; 2023 May; 12(9):10371-10384. PubMed ID: 36916290
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines.
    Kneissl J; Hartmann A; Pfarr N; Erlmeier F; Lorber T; Keller S; Zwingenberger G; Weichert W; Luber B
    J Cancer Res Clin Oncol; 2017 Apr; 143(4):573-600. PubMed ID: 27933395
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trastuzumab has opposing effects on SN-38-induced double-strand breaks and cytotoxicity in HER2-positive gastric cancer cells depending on administration sequence.
    Yamade M; Sugimoto M; Nishino M; Uotani T; Sahara S; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Miyajima H; Furuta T
    Anticancer Res; 2012 Jan; 32(1):105-14. PubMed ID: 22213294
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Autophagy-mediated HMGB1 release promotes gastric cancer cell survival via RAGE activation of extracellular signal-regulated kinases 1/2.
    Zhang QY; Wu LQ; Zhang T; Han YF; Lin X
    Oncol Rep; 2015 Apr; 33(4):1630-8. PubMed ID: 25652880
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation.
    Aigner A; Juhl H; Malerczyk C; Tkybusch A; Benz CC; Czubayko F
    Oncogene; 2001 Apr; 20(17):2101-11. PubMed ID: 11360194
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer.
    Hu X; Ma Z; Xu B; Li S; Yao Z; Liang B; Wang J; Liao W; Lin L; Wang C; Zheng S; Wu Q; Huang Q; Yu L; Wang F; Shi M
    Cancer Commun (Lond); 2023 Aug; 43(8):909-937. PubMed ID: 37434399
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
    Nonagase Y; Yonesaka K; Kawakami H; Watanabe S; Haratani K; Takahama T; Takegawa N; Ueda H; Tanizaki J; Hayashi H; Yoshida T; Takeda M; Chiba Y; Tamura T; Nakagawa K; Tsurutani J
    Oncotarget; 2016 Dec; 7(51):84860-84871. PubMed ID: 27768588
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
    Gomez-Martín C; Lopez-Rios F; Aparicio J; Barriuso J; García-Carbonero R; Pazo R; Rivera F; Salgado M; Salud A; Vázquez-Sequeiros E; Lordick F
    Cancer Lett; 2014 Aug; 351(1):30-40. PubMed ID: 24943493
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Predictive diagnosis of HER2 in gastric adenocarcinoma].
    Daum O; Skálová A; Rozkos T; Laco J
    Cesk Patol; 2011 Oct; 47(4):160-3. PubMed ID: 22145214
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin.
    Kim SY; Kim HP; Kim YJ; Oh DY; Im SA; Lee D; Jong HS; Kim TY; Bang YJ
    Int J Oncol; 2008 Jan; 32(1):89-95. PubMed ID: 18097546
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
    Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
    Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.
    Li Q; Li H; Jiang H; Feng Y; Cui Y; Wang Y; Ji Y; Yu Y; Li W; Xu C; Yu S; Zhuang R; Liu T
    Clin Transl Oncol; 2018 Jun; 20(6):695-702. PubMed ID: 29168107
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
    Cho JH; Lim JY; Cho JY
    World J Gastroenterol; 2017 Nov; 23(41):7407-7414. PubMed ID: 29151694
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HER2 testing in gastric cancer: An update.
    Abrahao-Machado LF; Scapulatempo-Neto C
    World J Gastroenterol; 2016 May; 22(19):4619-25. PubMed ID: 27217694
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.
    Pietrantonio F; Caporale M; Morano F; Scartozzi M; Gloghini A; De Vita F; Giommoni E; Fornaro L; Aprile G; Melisi D; Berenato R; Mennitto A; Volpi CC; Laterza MM; Pusceddu V; Antonuzzo L; Vasile E; Ongaro E; Simionato F; de Braud F; Torri V; Di Bartolomeo M
    Int J Cancer; 2016 Dec; 139(12):2859-2864. PubMed ID: 27578417
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
    Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
    Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma.
    Deguchi Y; Okabe H; Oshima N; Hisamori S; Minamiguchi S; Muto M; Sakai Y
    Gastric Cancer; 2017 May; 20(3):416-427. PubMed ID: 27517839
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Endothelin-A receptor in gastric cancer and enhanced antitumor activity of trastuzumab in combination with the endothelin-A receptor antagonist ZD4054.
    Shen W; Xi H; Li C; Bian S; Cheng H; Cui J; Wang N; Wei B; Huang X; Chen L
    Ann N Y Acad Sci; 2019 Jul; 1448(1):30-41. PubMed ID: 30937921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.